REPLY
13.12.2022 09:31:35 CET | Business Wire | Press release
POLIMI Graduate School of Management, Politecnico di Milano’s business school, and Reply, a company that has made innovation and technological specialisation its flagship, join forces to create a training path for excellence, which is aimed at preparing the professionals the industry needs to face future challenges.
Enrolment is now open for POLIMI Graduate School of Management Master's in "Digital Finance", which aims to offer highly qualified students a professional specialisation in financial services (fintech and insurtech) with a practical and experiential approach to innovation and new technologies such as: Artificial Intelligence, Machine Learning and Cloud.
The postgraduate course will start in April 2023 and will last 18 months. The Master’s includes a series of introductory courses on Business Management and Financial Services followed by a specialisation course aimed at training technical experts in the latest digital technologies (e.g. Cloud, AI, ML, etc.) applicable to the Financial Services market.
The lessons will be held online based on an executive model (lesson delivery will be on Fridays and Saturdays, for approximately 2 weekends per month) and the professors will be a mix of POLIMI Graduate School of Management academics and Reply specialists to combine theoretical lessons, workshops, hackathons and projects. The course will also include face-to-face meetings (2 or 3 over the course of the programme) at Politecnico di Milano laboratories or Reply offices. In the final stage of the course, students will carry out a 6-month work project at Reply, where they will put into practice the knowledge acquired in the classroom working in groups on live projects. The entire course is in English and open to international candidates.
The Master’s, at its first edition, is aimed at students with a Bachelor's or Master's degree in Computer Science, Computer Engineering, Cybersecurity, Automation Engineering, Electronics Engineering and Telecommunication Engineering which must be achieved by 31 March 2023 for three-year degrees, or by 31 July 2023 for Master's degrees.
Reply has committed to hire all candidates who are successful in their application and will bear the cost of the Master’s enrolment fees of those students who accept the job offer.
There are 50 places available and applications can be sent via the official website: master.reply.com. Applications will be accepted until all available places are filled, or until the deadline of March 13 2023.
More information available at master.reply.com.
Reply
Reply [MTA, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
POLIMI GRADUATE SCHOOL OF MANAGEMENT
At POLIMI Graduate School of Management we create meaningful paths for future business leaders and the businesses they will lead, guided by the over-arching belief that we have a crucial role to play in shaping a better world for all. Based in Milan, Italy’s main business centre, our school was created over 40 years ago as MIP Politecnico di Milano and today it is a not-for-profit Consortia Limited Company composed of the University and a group of leading Italian and multinational companies. We offer more than 40 masters degrees, including MBA and EMBA, and a catalogue of over 200 open programmes, along with customised training for companies. We continue to innovate and our digital learning systems allow us to seamlessly integrate personalized and continuous learning experiences into our programmes and have placed us amongst the top-ranked Online MBA rankings globally. As part of the School of Management of Politecnico di Milano, we are among the few “Triple Crown” accredited schools across the world. With over 15,000 alumni and 3,000 students every year we are an innovative and entrepreneurial community made up of diverse people and partners. We see the power of relationships as a constant source of enrichment, innovation and inspiration, personal and professional. At POLIMI Graduate School of Management we take sustainability seriously and continue to work towards a better, more conscious, more equitable and more inclusive future. In 2020 we were the first European Business School to become a B Corp certified business. www.gsom.polimi.it/en/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221213005091/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents23.4.2026 13:29:00 CEST | Press release
Mangaciclanol, if approved, could transform contrast-enhanced MR imaging by offering an alternative to - or even replacing - gadolinium-based MRI agentsA manganese-based MRI contrast agent could address concerns with gadolinium-based contrast agents around retention in the body, security of supply, and the environment, with mangaciclanol’s clinical development under FDA Fast Track designationThe program demonstrates GE HealthCare’s commitment to advancing novel imaging agents to address unmet patient needs GE HealthCare (Nasdaq: GEHC) today announced the first patient has been dosed in the international, multi-center Phase 2/3 LUMINA clinical trial of its manganese-based magnetic resonance imaging (MRI) contrast agent, mangaciclanol, at Mayo Clinic in Rochester, Minnesota. Mangaciclanol, if approved, could offer an alternative to – or even replace – gadolinium-based MRI contrast agents, the current standard of care. The investigational agent has been granted Fast Track designation by t
Croma Pharma Launches AI-Driven Tech Venture to Revolutionize Aesthetic Medicine via Clinicore Platform23.4.2026 13:13:00 CEST | Press release
New structure to drive AI-powered innovation and international expansion Croma Pharma has launched a strategic joint venture to accelerate the development of Clinicore, its premium digital solution for aesthetic practices. This dedicated entity will focus on scaling the next generation of the platform while ensuring full continuity for existing users. Clinicore: Elevating Practice Excellence through AI Clinicore is a specialized SaaS (Software as a Service) solution designed to optimize the daily operations of aesthetic clinics. By automating patient management, scheduling, and administrative workflows, it enables healthcare professionals to focus entirely on patient care. A core element of the new strategy is a strong focus on Artificial Intelligence. Clinicore is evolving into a smart assistant, utilizing AI-driven features for automated treatment documentation, intelligent onboarding tools, and advanced process automation. This ensures that clinics can operate at maximum efficiency
NIQ Launches Commerce Lab to Build the Data and Measurement Layer for AI-Driven Commerce23.4.2026 13:00:00 CEST | Press release
NielsenIQ (NYSE: NIQ) today announced the launch of NIQ Commerce Lab, where the company is building the technology infrastructure for AI-driven commerce. The Lab will develop the data platforms, APIs, and measurement systems that power how products are discovered, evaluated, and purchased in AI-mediated environments. This includes what the industry often refers to as agentic commerce, but extends across quick commerce, social commerce, and other emerging channels—where AI is becoming the common layer shaping how consumers navigate choices and how decisions are made in real time. AI systems are rapidly moving from supporting decisions to making them—playing an increasingly central role in how commerce operates. Their effectiveness depends on the intelligence behind them. AI is Becoming the Operating Layer of Global Commerce NIQ ensures that the intelligence behind these systems is accurate, complete, and grounded in real-world behavior—reflecting how consumers actually buy, what product
Chiesi Reports Strong FY2025 Financial and Sustainability Results and Announces Leadership Transition Highlights23.4.2026 12:10:00 CEST | Press release
Strong FY2025 financial and sustainability results; leadership transition will support continuity and long-term growth Revenue up 8.2% to €3.6bn with double-digit growth in Rare Diseases and U.S. market Air sales at €1.886bn, growing 3.9% vs. 2024 - Care sales at €904m growing 13.3% vs. 2024 - Rare sales at €906m, growing 22.3% vs. 2024 Giuseppe Accogli leaving to pursue another opportunity, Group CFO Jean-Marc Bellemin named Interim CEO while new CEO search is underway Record €885m Research & Development (R&D) investment underscores continued commitment to innovation across respiratory, rare disease and specialty care Sustainability leadership further strengthened through B Corp recertification and progress on Carbon Minimal Inhaler (CMI) innovation Chiesi Group (“Chiesi”), an international research‑focused biopharmaceutical company and certified B Corp, today announced its financial results for the year ended 31 December 2025. Chiesi reported €3.625 billion in consolidated revenues,
REPLY S.p.A.: Shareholders’ Meeting Approves the 2025 Financial Statements23.4.2026 12:05:00 CEST | Press release
Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024);Group net profits of €250.9 million (€211.1 million in 2024).Approval of the proposal to distribute a dividend of €1.35 per share.Approval of the plan for the purchase and/or disposal of treasury shares. The General Shareholders’ meeting of Reply S.p.A. [EXM, STAR: REY] held today approved the Financial Statements for the financial year 2025, confirming the distribution of a gross dividend of €1.35 per share. The dividend will be paid on 20 May 2026, with dividend date set on 18 May 2026 (record date on 19 May 2026). Approval of the 2025 financial statements The Reply Group closed the 2025 financial year with a consolidated turnover of €2,483.6 million, recording a 8.0% increase compared to €2,300.5 million in 2024. Consolidated EBITDA was €467.6 million, up 13.9% compared to €410.6 million recorded for the year 2024. EBIT, from January to December, was €397.1 million, up 18.5% compared to €330.4 million recorded for
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
